m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03257)
Name
BB-1101
Synonyms
BB-1101; CHEMBL432079; SCHEMBL1844243; BDBM50070453
    Click to Show/Hide
Status
Terminated
Structure
Formula
C21H31N3O4
InChI
1S/C21H31N3O4/c1-5-9-16(20(26)24-28)17(12-14(2)3)19(25)23-18(21(27)22-4)13-15-10-7-6-8-11-15/h5-8,10-11,14,16-18,28H,1,9,12-13H2,2-4H3,(H,22,27)(H,23,25)(H,24,26)/t16-,17+,18-/m0/s1
InChIKey
GKHRDWHFKKUYAX-KSZLIROESA-N
PubChem CID
9908389
TTD Drug ID
D05VNG
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-1 (MMP-1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for BB-1101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). [1], [2]
Matrix metalloproteinase-2 (MMP-2)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BB-1101. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BB-1101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [4], [5]
Matrix metalloproteinase-3 (MMP-3)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for BB-1101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). [2], [6]
References
Ref 1 METTL3 involves the progression of osteoarthritis probably by affecting ECM degradation and regulating the inflammatory response. Life Sci. 2021 Aug 1;278:119528. doi: 10.1016/j.lfs.2021.119528. Epub 2021 Apr 21.
Ref 2 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8. doi: 10.1016/s0960-894x(98)00186-3.
Ref 3 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 4 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 5 RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019 Aug;29(4):382-389. doi: 10.1097/CMR.0000000000000580.
Ref 6 METTL3 Promotes Activation and Inflammation of FLSs Through the NF-KappaB Signaling Pathway in Rheumatoid Arthritis. Front Med (Lausanne). 2021 Jul 6;8:607585. doi: 10.3389/fmed.2021.607585. eCollection 2021.